 SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody technology platform, today announced that on February 15, 2021, the Company granted a new employee an option to purchase a total of 65,000 shares of the Companys common stock at an exercise price per share equal to 8.64, which was the closing trading price on February 16, 2021, the date of the grant. 